交易中 11-18 11:14:06 美东时间
-1.390
-0.55%
Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.
33分钟前
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
11-16 22:23
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment
07-14 02:23
Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AXP, see other ratings and consider buying BIIB.
07-13 19:07
Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key priorities. PT increased to $256.
06-29 23:27
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.
06-29 18:08
Records from June 8, 2026 indicate that Representative Maria Elvira Salazar of ...
06-09 23:15
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and other stock views.
06-08 21:58
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial
06-01 16:40
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32